RCMNY
AKBA icon

Rubric Capital Management (New York)’s Akebia Therapeutics AKBA Stock Holding History

Rubric Capital Management (New York)’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-604,481
Closed -$4.95M – 55
2019
Q1 		$4.95M Sell
604,481
-465,614
-44% -$3.2M 0.46% 50
2018
Q4 		$5.92M Buy
1,070,095
+767,364
+253% +$6.01M 0.73% 35
2018
Q3 		$2.67M Buy
+302,731
New +$2.71M 0.28% 45

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rubric Capital Management (New York)'s AKBA Position: Q2 2019 in Review

Rubric Capital Management (New York) sold out of Akebia Therapeutics (AKBA) in Q2 2019, closing a stake of 604,481 shares — an estimated $4.95M sold.

Rubric Capital Management (New York) first reported a position in AKBA in Q3 2018 and held it in 3 quarters. The position peaked at $5.92M in Q4 2018. 151 funds tracked by Wall St. Rank hold AKBA as of Q2 2019.

  • Rubric Capital Management (New York) reported no remaining Akebia Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 604,481 Akebia Therapeutics shares in Q2 2019, an estimated $4.95M.
  • Rubric Capital Management (New York) first reported a position in Akebia Therapeutics in Q3 2018 and held it in 3 quarters.
  • Rubric Capital Management (New York)'s Akebia Therapeutics position peaked at $5.92M in Q4 2018.
  • 151 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2019.

Based on Rubric Capital Management (New York)'s 13F filing for Q2 2019, filed 13 Aug 2019.